Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 4/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710414 | 0.99 | CTSK (0.40) | CTSKHAO1ARCTSLHDAC6 | |
| SCHEMBL13400233 | 0.82 | DDB1 (0.48) | CTSKHAO1ARCTSL | |
| SCHEMBL3389803 | 0.79 | ALDH1A1 (0.41) | HAO1 | |
| SCHEMBL1726051 | 0.78 | PPARD (0.35) | HAO1MTNR1AMTNR1B | |
| SCHEMBL1710379 | 0.77 | GAA (0.35) | HAO1MTNR1AMTNR1B | |
| SCHEMBL613918 | 0.76 | POLB (0.40) | CTSKHAO1HDAC6MTNR1AMTNR1B | |
| SCHEMBL1710629 | 0.75 | AR (0.41) | CTSKHAO1AR | |
| SCHEMBL1710568 | 0.75 | AR (0.46) | CTSKHAO1ARCTSLCTSB | |
| SCHEMBL13400260 | 0.74 | HDAC6 (0.44) | CTSKARCTSLHDAC6MTNR1A | |
| SCHEMBL13400308 | 0.74 | AR (0.38) | CTSKARCTSLHDAC6CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | CTSK 2722/4885HAO1 2660/4885AR 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.